A Randomised, DB, Placebocontrolled, Multicentre, Multinational Phase II/III Study to Assess the Efficacy and Safety of Three Different Dose Regimens of Oralgen Grasspollen in Patients With Grasspollen Related Allergic Rhinoconjunctivitis.
Phase of Trial: Phase II/III
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- 21 Dec 2007 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History